An endless series of crises roiling ocean shipping in the post-COVID 19 era is resulting in a change in “carrier DNA.”

As uncertainty has become the new norm for supply chains, previously tried-and-true crisis management strategies are no longer equipped to keep up with the pace of today's disruptions.

Supply chain leaders love to talk about their push for “digitization” of key processes. But their hiring patterns aren’t always lining up with that rhetoric.

Already in 2025, we've seen the direct and indirect impacts of climate change on the price and availability of essential foods.

U.S.-based companies are also likely to suffer because of reciprocal tariffs imposed by America’s trading partners in retaliation, threatening profit from exports. 

Don’t expect the Trump tariffs to trigger a boom in domestic manufacturing in the U.S. — or an end to the growth of “nearshored” production capacity in Mexico.

Prices will rise, maybe wages will too. The question is whether Trump’s new tariff regime will pay off. 

Ending de minimis requirements altogether could mean more paperwork, longer processing times, and higher costs for everyone from shippers to consumers.

Some argue that Trump is simply using threats of injurious trade penalties in order to win smaller, different concessions. Others see a far more dramatic agenda at play.

Can the U.S. pharmaceutical supply chain come home — or, at least, get closer to it?